SMMT
NASD Summit Therapeutics Inc$16.75 ↓ -0.00 (-0.03%) Trading Down from the previous close of $16.76, $0.57 below the day’s high of $17.32
- YTD change
- -4.23%
- vs 20-day SMA
- -1.68%
- vs 200-day SMA
- +2.39%
Price ranges
Price & Performance
-2.69 (-13.88%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 54.6% away from all-time highs of $36.91
- SMMT is down 4% since the beginning of the year
- SMMT is down 20% over the past 12 months
- SMMT is up 15% over the past 1 month
- 28% of all SMMT investors are betting against SMMT
SMMT reads not so good: price sits above one of the two key moving averages, the 12-month move is -20.0%.
- Previous minute
- -$0.01
- Last hour
- -$0.03
- Last 5 days
- +2.26%
- vs 8-day SMA
- +2.27%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
